<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 15, 2000
LJL BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
000-23647
(Commission File Number)
DELAWARE 77-0360183
(State or other jurisdiction of (I.R.S. Employer Identification No.
incorporation)
405 TASMAN DRIVE
SUNNYVALE, CA 94089
(Address of principal executive offices, with zip code)
(408) 541-8787
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
On February 15, 2000, LJL BioSystems, Inc. announced that Richard
Eglen, Ph.D. joined LJL BioSystems as Senior Vice President, Assay
Technologies. Further details regarding this announcement are contained in
the company's news release dated February 15, 2000 attached as an exhibit
hereto and incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Exhibits:
99.12 LJL BioSystems, Inc. News Release dated February 15,
2000
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LJL BIOSYSTEMS, INC.
Date: February 16, 2000 By: /s/ Lev J. Leytes
------------------------
Lev J. Leytes
President and CEO
-3-
<PAGE>
Exhibit 99.12
CONTACTS:
LJL BIOSYSTEMS, INC.: MEDIA RELATIONS:
LARRY TANNENBAUM FRIESTEDT INTERNATIONAL
CFO AND SENIOR VICE PRESIDENT SUSANNE FRIESTEDT
408-548-0542 619-223-8844
[email protected] [email protected]
- ---------------------- ------------------
Richard Eglen, Ph.D. Joins LJL BioSystems as Senior Vice President,
Assay Technologies
SUNNYVALE, CA - FEBRUARY 15, 2000 - LJL BioSystems, Inc. (NASDAQ: LJLB) today
announced the appointment of Richard Eglen, Ph.D. as Senior Vice President,
Assay Technologies. Dr. Eglen will be responsible for the strategy,
development, and commercialization of the Company's assay technologies. Dr.
Eglen joins LJL from Roche Bioscience, where he held the position of Vice
President and Director of the Center for Biological Research. His various
responsibilities included global coordination of High Throughput Screening
for Roche.
"Dr. Eglen's appointment represents another important milestone in building
our company," stated Lev J. Leytes, Chairman and CEO of LJL. "As the newest
member of our senior management team, we believe that Dr. Eglen's impressive
background and record of success, will help drive the expansion of LJL's
consumable assay business. With a growing installed base of over 100
instrument platforms we will continue our emphasis on the consumable assay
business which we believe can be one of the cornerstones of our future
expansion."
Dr. Eglen is an international authority in the molecular pharmacology of
G-protein coupled receptors, ligand and voltage gated ion channels. He is the
author of over 200 peer-reviewed papers and books and currently serves on
several editorial boards and international committees. Dr. Eglen, who has a
Ph. D. in pharmacology, has led drug discovery programs from target
identification to early clinical trial. He brings to LJL over 16 years of
experience in the pharmaceutical industry.
ABOUT LJL BIOSYSTEMS, INC. LJL BioSystems supplies infrastructure tools to
pharmaceutical and biotech companies engaged in the highly competitive search
for new medicines in the genomics era. LJL's family of proprietary products,
marketed as CRITERION(TM), consists of instruments, consumables, and
services. The Company intends to establish CRITERION as the gold standard for
addressing many of the key bottlenecks in drug discovery. In August 1999, LJL
launched its Genomics Science Group to further commercialize the Company's
technology in SNP genotyping. Since then, several leading genomics customers
have adopted the LJL HEFP-SNP genotyping platform.
<PAGE>
LJL's worldwide customers include, among others, AstraZeneca, Bristol Myers
Squibb, Eli Lilly and Company, Johnson and Johnson, Merck and Co., Tularik,
Inc., Millennium Pharmaceuticals, Inc., Pharmacia & Upjohn, DuPont
Pharmaceuticals Company, Amgen, Inc., Monsanto Company and SmithKline
Beecham. LJL is headquartered in Sunnyvale, California and has a subsidiary
in the United Kingdom. Additional information on LJL and CRITERION technology
can be found at www.ljlbio.com.
FORWARD-LOOKING STATEMENTS Except for the historical information contained
herein, the matters discussed in this news release are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act,
including statements regarding LJL's "expectations", "goals", "beliefs",
"hopes", "designs", "intentions", "strategies" or the like. Such statements
are subject to risks and uncertainties that could cause actual results to
differ materially, including such factors, among others, as the impact of
competitive products and pricing, the timely development and market
acceptance of new products, the ability to raise capital, concentration of
HTS and Ultra-HTS markets, market conditions, the mix between domestic and
international sales, manufacturing and cost of LJL's products, dependence on
collaborative partners, the enforcement of intellectual property rights, and
uncertainties relating to sole source suppliers, technological approaches,
FDA and other regulatory approvals. These and other risk factors are
discussed in LJL's Report on Form 10-K, filed March 30, 1999, Reports on Form
10-Q filed May 14, 1999, August 16, 1999 and November 15, 1999 and Form S-3
dated July 22, 1999 (see, in particular, Risk Factors and Management's
Discussion and Analysis of Financial Condition and Results of Operations).
LJL disclaims any intent or obligation to update these forward-looking
statements. As a result of these and other factors, LJL expects to experience
significant fluctuations in operating results, and there can be no assurance
that LJL will become or remain consistently profitable in the future.
For information on LJL BioSystems, Inc., contact Larry Tannenbaum, Chief
Financial Officer, at 408-548-0542 or [email protected].
